 Your new post is loading...
 Your new post is loading...
|
Scooped by
BigField GEG Tech
July 4, 6:33 AM
|
Researchers at the National University of Singapore (NUS) have developed a scalable, non-viral technology that efficiently delivers genetic material into human immune cells.
|
Scooped by
BigField GEG Tech
June 24, 10:01 AM
|
A new type of immunotherapy that targets aggressive blood cancers shows promising results alongside manageable side effects, according to the results of an international phase 1/2 clinical trial led by researchers at Washington University School of Medicine in St. Louis.
|
Scooped by
BigField GEG Tech
May 23, 6:22 AM
|
Researchers in South Korea have proposed a novel cancer immunotherapy approach that could complement existing CAR-T (Chimeric Antigen Receptor T-cell) treatments.
|
Scooped by
BigField GEG Tech
April 30, 12:28 PM
|
Researchers from the J. Craig Venter Institute (JCVI), the Friedrich-Loeffler-Institut (FLI), and the International Livestock Research Institute (ILRI) have developed a reverse genetics system for African swine fever virus (ASFV).
|
Scooped by
BigField GEG Tech
April 15, 6:20 AM
|
Researchers at the University of Colorado Anschutz Medical Campus have successfully developed a supercharged iteration of CAR-T cell therapy that can enhance the effectiveness and longevity of the cells, particularly against cancer cells that are harder for prior CAR-T therapies to detect and fight.
|
Scooped by
BigField GEG Tech
April 7, 5:08 AM
|
New precision genome editing technologies are transforming the therapeutic landscape for patients with certain cancers and genetic diseases.
|
Scooped by
BigField GEG Tech
March 18, 7:50 AM
|
The FDA has granted orphan drug and rare pediatric disease designations to Arbor Biotechnologies' ABO-101, a gene-editing therapeutic candidate for primary hyperoxaluria type 1. The one-time treatment aims to reduce oxalate production in patients with this rare genetic kidney disease.
|
Scooped by
BigField GEG Tech
March 14, 11:41 AM
|
|
Scooped by
BigField GEG Tech
January 7, 6:20 AM
|
Cell-to-cell communication through nanosized particles, working as messengers and carriers, can now be analyzed in a whole new way, thanks to a new method involving CRISPR gene-editing technology.
|
Scooped by
BigField GEG Tech
December 4, 2024 6:33 AM
|
In the quest to enhance the efficacy of chimeric antigen receptor T (CAR-T) cell therapy against hepatocellular carcinoma (HCC), a recent study has identified a pivotal role for CD39 expression in modulating the function of CAR-T cells.
|
Scooped by
BigField GEG Tech
November 25, 2024 9:59 AM
|
Ludwig Cancer Research scientists have devised new types of chimeric antigen-receptor (CAR) T cells-;a type of cancer immunotherapy-;that can be switched on to varying degrees of intensity and then switched off on demand with existing drugs.
|
Scooped by
BigField GEG Tech
November 15, 2024 10:07 AM
|
Virologist Beata Halassy says self-treatment worked and was a positive experience — but researchers warn that it is not something others should try.
|
Scooped by
BigField GEG Tech
October 14, 2024 8:28 AM
|
Researchers in France report the correction of three duplications in the dystrophin gene in cells from Duchenne muscular dystrophy patients, using CRISPR-Cas9 gene editing and a single guide RNA. The findings highlight the potential of using CRISPR-Cas9 to correct DMD duplications in exons that are not addressed by any of the fou
|
|
Scooped by
BigField GEG Tech
July 4, 3:29 AM
|
AbbVie said on Monday it would acquire privately held cell therapy developer Capstan Therapeutics in a deal worth up to $2.1 billion, expanding its product pipeline with experimental treatments for autoimmune diseases.
|
Scooped by
BigField GEG Tech
May 26, 6:57 AM
|
The tumor microenvironment (TME) is a complex and dynamic network consisting of tumor cells, immune cells, stromal cells, extracellular matrix (ECM), cytokines, and growth factors, all interacting to influence tumorigenesis, progression, and metastasis.
|
Scooped by
BigField GEG Tech
May 14, 11:43 AM
|
A team of researchers from the Hospital del Mar Research Institute, the Universitat Autònoma de Barcelona and the Pompeu Fabra University has developed a new tool that allows modifying these NK cells to make them immune to the tumor’s defense mechanism.
|
Scooped by
BigField GEG Tech
April 16, 3:58 AM
|
Allogene Therapeutics recently released exciting results from the Phase 1 ALPHA/ALPHA2 trials of the Allogeneic CAR T 'Cemacabtagene Ansegedleucel/ALLO-501' in Relapsed/Refractory Large B-Cell Lymphoma.
|
Scooped by
BigField GEG Tech
April 8, 6:34 AM
|
The potential of regenerative medicine in the clinical space is vast, given its ability to repair and replace damaged tissues, restore lost functions …
|
Scooped by
BigField GEG Tech
March 20, 11:51 AM
|
Within a large group of more than 700 patients treated with CAR T cell therapy, researchers found no evidence that the therapy itself caused any type of secondary cancer in the modified T cells, according to new analysis reported today in Nature Medicine from the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center.
|
Scooped by
BigField GEG Tech
March 17, 11:19 AM
|
Researchers have identified a method to enhance the effectiveness of a promising cancer treatment. They found that modifying a specific gene improves the ability of immune cells to combat cancer for an extended period, potentially reducing the chance of cancer recurring.
|
Scooped by
BigField GEG Tech
February 3, 10:00 AM
|
Russell W. Jenkins, MD, PhD, a physician investigator in the Krantz Family Center for Cancer Research at the Mass General Cancer Center and an assistant professor of Medicine at Harvard Medical School, is senior author of a new study in Cancer Immunology Research, "TBK1 is Identified as a Therapeutic Strategy to Enhance CAR T-Cell Efficacy Using Patient-Derived Organotypic Tumor Spheroids".
|
Scooped by
BigField GEG Tech
December 13, 2024 6:29 AM
|
Nature Medicine asks leading researchers to name their top clinical trial for 2025, from gene therapies for prion disease and sickle-cell disease to digital tools for cancer and mental health.
|
Scooped by
BigField GEG Tech
December 2, 2024 7:05 AM
|
Researchers in Italy and Australia report a triple combination strategy involving CRISPR that boosts the response of neuroblastoma to immunotherapy.
|
Scooped by
BigField GEG Tech
November 22, 2024 6:49 AM
|
CRISPR is a revolutionary tool that allows scientists to precisely modify the genome and gene expression of cells in any organism. It's a reagent-;a substance that facilitates a reaction-;that combines an enzyme with a programmable RNA capable of locating specific genetic sequences. Once guided to the correct spot, the enzyme acts like a pair of scissors, cutting, replacing, or deleting sequences of DNA.
|
Scooped by
BigField GEG Tech
October 16, 2024 4:25 AM
|
A new approach for delivering miniature research tools into the interior of egg cells and embryos has been developed at the Marine Biological Laboratory (MBL), resolving a major bottleneck to using the gene-editing tool CRISPR-Cas9 in many research organisms.
|
Researchers at the University of Tokyo have developed a groundbreaking CRISPR-based barcoding system to study small extracellular vesicles (sEVs), nanosized particles crucial in intercellular communication and disease progression. The system uses CRISPR gene-editing technology to introduce RNA barcodes into sEVs, allowing thousands of genes to be analyzed simultaneously in a single pooled experiment. CIBER (CRISPR-assisted individually barcoded extracellular vesicle-based release regulator) offers detailed insights into sEV subpopulations, enabling more efficient and comprehensive studies than conventional methods. This innovation opens new pathways for sEV-based diagnostics and therapeutic applications.